Pancreatic Cancer Early Detection Consortium

Launched by ARBOR RESEARCH COLLABORATIVE FOR HEALTH · Jul 19, 2021

Keywords

ClinConnect Summary

The Pancreatic Cancer Early Detection Consortium (PRECEDE) is a research study aimed at finding ways to detect pancreatic ductal adenocarcinoma (PDAC) earlier and prevent it from developing. The study is looking for individuals who have a family history of pancreatic cancer or specific genetic changes that increase their risk of developing PDAC. By gathering information from these participants over time, researchers hope to better understand how to identify the disease at an early stage.

To be eligible for this study, participants should be between the ages of 50 and 80 and meet certain criteria, such as having multiple family members with pancreatic cancer or carrying specific genetic markers linked to the disease. Participants can expect regular evaluations and to contribute samples, like blood or saliva, for research purposes. This study is important because it aims to improve early detection of pancreatic cancer, which could lead to better treatment outcomes. If you or a family member think you might qualify, consider discussing it with your doctor for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:
• • Cohort 1
• Individuals without history of PDAC meeting any of the following criteria:
• • 1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
• • 2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
• • 3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
• • 4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
• • 5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
• • 6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
• • Cohort 2
• Individuals without history of PDAC meeting any of the following criteria:
• • 1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
• • 2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
• • 3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
• • Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
• • Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
• • Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
• • Cohort 6a
• Individuals diagnosed with PDAC after enrollment in PRECEDE meeting any of the following criteria:
• • 1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
• • 2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
• • Cohort 6b
• Individuals with a personal history of PDAC meeting any of the following criteria:
• • 1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
• • 2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
• • 3. Diagnosed ≤ age 45
• • Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)
• Exclusion Criteria:
• • Individuals not meeting the criteria above.